International Myeloma Society Educational Workshop in Belgrade, Serbia 2026

Description

+ Include:  videos + file sub vtt +  pdf, size:  GB

+ Target Audience: hematologists, oncologists

+ Sample video: contact me for sample video

+ Information:

The International Myeloma Society Educational Workshop will be held in Belgrade, Serbia, from March 13 – 14, 2026, in collaboration with the Balkan Myeloma Study Group and the Serbian Myeloma Group. The event offers a dynamic program focused on the diagnosis, treatment, and monitoring of plasma cell malignancies. Attendees will benefit from lectures, roundtable discussions, and point-counterpoint conversations addressing current practices, challenging questions, and clinical cases.

Learning Objectives

Based on the program sessions, learners will be able to:

• Implement updated diagnostic testing, imaging techniques, and MRD testing for Multiple Myeloma.

• Apply new risk stratification models and effectively manage both Smoldering Myeloma and Newly Diagnosed Multiple Myeloma (transplant eligible and non-transplant eligible).

• Determine optimal sequencing strategies for Relapsed and Refractory Multiple Myeloma and explore novel treatments beyond cell therapies.

• Understand and incorporate novel immune strategies, including CAR T Cells and Bispecific T Cell Engagers, into clinical practice.

• Manage myeloma-related complications such as bone disease, renal failure, and infections through appropriate supportive care and vaccinations.

• Update knowledge on the management of other plasma cell disorders like Waldenström’s Macroglobulinemia and AL Amyloidosis.

• Address challenging clinical scenarios, including relapse after T cell redirected therapies, extramedullary disease, and incorporating frailty into treatment algorithms.

Target Audience

• This workshop is intended for hematologists, oncologists, researchers, and other healthcare professionals involved in the diagnosis, treatment, and ongoing care of patients with plasma cell malignancies.
• Best for Hematologists and Oncologists.

Topics

• Plenary Talks:

  • From Biology to Therapy: The Current Landscape of Multiple Myeloma.

  • The Future of Multiple Myeloma.

• Diagnosis, Risk Stratification, and Monitoring of Plasma Cell Disorders:

  • Diagnostic Testing for Multiple Myeloma, Risk Stratification and Follow-up.

  • Update and Recommendations on Imaging Techniques in Myeloma.

  • MRD Testing in Multiple Myeloma.

  • New Risk Stratification in Smoldering and Multiple Myeloma.

  • Live Panel Discussion: Diagnosis and Follow Up of Patients.

• Smoldering MM and Newly Diagnosed Multiple Myeloma:

  • Management of Clinical Significance/Smoldering Myeloma.

  • Management of Newly Diagnosed MM Transplant Eligible.

  • Management of Newly Diagnosed MM Non-transplant Eligible.

  • Live Panel Discussion: How to Manage SMM and NDMM.

• Relapsed and Refractory Multiple Myeloma:

  • Optimal Sequencing for RRMM Patients in their 1st and 2nd Relapse.

  • Novel Treatments for MM Besides Cell Therapies and Bispecifics.

  • Live Panel Discussion: Sequencing of Therapies in RR MM.

• Novel Immune Strategies:

  • CAR T Cells.

  • Bispecific T Cell Engagers.

  • Live Panel Discussion: Incorporating Novel Immunotherapies in Practice.

• Supportive Care:

  • Bone Disease and Renal Failure.

  • Infection and Vaccinations.

  • Live Panel Discussion: Managing Myeloma Related Complications.

• Update on Other Plasma Cell Disorders:

  • Waldenström’s Macroglobulinemia.

  • AL Amyloidosis.

  • Live Panel Discussion: Managing Other Dysporteinemias.

• Challenging Questions in MM:

  • Relapse After T Cell Redirected Therapies.

  • Extramedullary Disease and Plasma Cell Leukemia.

  • Incorporating Frailty into Treatment Algorithms for MM.

  • Live Panel Discussion.